• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sanofi

    7/2/25 8:25:36 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    6-K 1 d27662d6k.htm 6-K 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    For the month of July 2025

    Commission File Number: 001-31368

    SANOFI

    (Translation of registrant’s name into English)

    46, avenue de la Grande Armée, 75017 Paris, FRANCE

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     

    1


    In June 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

    Exhibit Index

     

    Exhibit No.    Description        
    Exhibit 99.1    Press Release dated June 25, 2025: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
    Exhibit 99.2    Press Release dated June 30, 2025: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: July 2, 2025     SANOFI
        By      /s/  

    Alexandra Roger

          Name: Alexandra Roger
          Title: Head of Legal Corporate & Finance

     

    3

    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi upgraded by Deutsche Bank

      Deutsche Bank upgraded Sanofi from Sell to Hold

      1/30/25 3:33:45 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      7/2/25 8:25:36 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Sanofi

      11-K - Sanofi (0001121404) (Filer)

      6/27/25 4:52:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Sanofi

      11-K - Sanofi (0001121404) (Filer)

      6/27/25 4:49:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

      New fund supports nonprofit partners working to address social drivers of health and strengthen community well-beingCAMBRIDGE, Mass., June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and well-being in historically undersupported communities. The initiative is part of Sanofi's broader commitment to improve equitable access to healthcare by addressing structural factors, such as lack of access to housing, food, and behavioral health. Launched earlier this year, the Fund strategically inves

      6/26/25 8:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care